Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis.

IF 3.1 Q2 PERIPHERAL VASCULAR DISEASE

High Blood Pressure & Cardiovascular Prevention Pub Date : 2023-05-01 Epub Date: 2023-04-15 DOI:10.1007/s40292-023-00574-5

Marco Zuin, Gianluca Rigatelli, Claudio Bilato, Giampaolo Pasquetto, Alberto Mazza

{"title":"Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis.","authors":"Marco Zuin, Gianluca Rigatelli, Claudio Bilato, Giampaolo Pasquetto, Alberto Mazza","doi":"10.1007/s40292-023-00574-5","DOIUrl":null,"url":null,"abstract":"Introduction: Arterial Hypertension (HT) has been described as a common comorbidity and independent risk factor of short-term outcome in COVID-19 patients. However, data regarding the risk of new-onset HT during the post-acute phase of COVID-19 are scant.Aim: We assess the risk of new-onset HT in COVID-19 survivors within one year from the index infection by a systematic review and meta-analysis of the available data.Methods: Data were obtained searching MEDLINE and Scopus for all studies published at any time up to February 11, 2023, and reporting the long-term risk of new-onset HT in COVID-19 survivors. Risk data were pooled using the Mantel-Haenszel random effects models with Hazard ratio (HR) as the effect measure with 95% confidence interval (CI). Heterogeneity among studies was assessed using I2 statistic.Results: Overall, 19,293,346 patients (mean age 54.6 years, 54.6% males) were included in this analysis. Of them, 758,698 survived to COVID-19 infection. Over a mean follow-up of 6.8 months, new-onset HT occurred to 12.7 [95% CI 11.4-13.5] out of 1000 patients survived to COVID-19 infection compared to 8.17 [95% CI 7.34-8.53] out of 1000 control subjects. Pooled analysis revealed that recovered COVID-19 patients presented an increased risk of new-onset HT (HR 1.70, 95% CI 1.46-1.97, p < 0.0001, I2 = 78.9%) within seven months. This risk was directly influenced by age (p = 0.001), female sex (p = 0.03) and cancer (p < 0.0001) while an indirect association was observed using the follow-up length as moderator (p < 0.0001).Conclusions: Our findings suggest that new-onset HT represents an important post-acute COVID-19 sequelae.","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-023-00574-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Arterial Hypertension (HT) has been described as a common comorbidity and independent risk factor of short-term outcome in COVID-19 patients. However, data regarding the risk of new-onset HT during the post-acute phase of COVID-19 are scant.

Aim: We assess the risk of new-onset HT in COVID-19 survivors within one year from the index infection by a systematic review and meta-analysis of the available data.

Methods: Data were obtained searching MEDLINE and Scopus for all studies published at any time up to February 11, 2023, and reporting the long-term risk of new-onset HT in COVID-19 survivors. Risk data were pooled using the Mantel-Haenszel random effects models with Hazard ratio (HR) as the effect measure with 95% confidence interval (CI). Heterogeneity among studies was assessed using I² statistic.

Results: Overall, 19,293,346 patients (mean age 54.6 years, 54.6% males) were included in this analysis. Of them, 758,698 survived to COVID-19 infection. Over a mean follow-up of 6.8 months, new-onset HT occurred to 12.7 [95% CI 11.4-13.5] out of 1000 patients survived to COVID-19 infection compared to 8.17 [95% CI 7.34-8.53] out of 1000 control subjects. Pooled analysis revealed that recovered COVID-19 patients presented an increased risk of new-onset HT (HR 1.70, 95% CI 1.46-1.97, p < 0.0001, I² = 78.9%) within seven months. This risk was directly influenced by age (p = 0.001), female sex (p = 0.03) and cancer (p < 0.0001) while an indirect association was observed using the follow-up length as moderator (p < 0.0001).

Conclusions: Our findings suggest that new-onset HT represents an important post-acute COVID-19 sequelae.

Abstract Image

查看原文本刊更多论文

新冠肺炎康复后发生新发性动脉高压的风险：系统回顾和Meta-analysis。

简介：动脉高血压（HT）已被描述为新冠肺炎患者常见的合并症和短期结果的独立危险因素。然而，关于新冠肺炎急性期后新发HT风险的数据很少。目的：我们通过对现有数据的系统回顾和荟萃分析，评估新冠肺炎幸存者在指数感染后一年内发生新发HT的风险。方法：检索截至2023年2月11日在任何时间发表的所有研究的MEDLINE和Scopus，并报告新冠肺炎幸存者新发HT的长期风险。风险数据使用Mantel-Haenszel随机效应模型进行汇总，风险比（HR）作为95%置信区间（CI）的效应度量。研究之间的异质性使用I2统计进行评估。结果：总体而言，19293346名患者（平均年龄54.6岁，54.6%为男性）被纳入本分析。其中758698人因感染新冠肺炎而幸存。在6.8个月的平均随访中，1000名新冠肺炎感染患者中有12.7人出现新发HT[95%CI 11.4-13.5]，而1000名对照受试者中有8.17人[95%CI 7.34-8.53]。汇总分析显示，新冠肺炎康复患者出现新发HT的风险增加（HR 1.70，95%CI 1.46-1.97，p 2. = 78.9%）。这种风险直接受到年龄的影响（p = 0.001），女性（p = 0.03）和癌症（p 结论：我们的研究结果表明，新出现的HT是新冠肺炎急性期后的一种重要后遗症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

High Blood Pressure & Cardiovascular Prevention PERIPHERAL VASCULAR DISEASE-

CiteScore

5.70

自引率

3.30%

发文量

期刊介绍： High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes: Invited ''State of the Art'' reviews. Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.